 Kazia Therapeutics Ltd NASDAQ: KZIA has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB OTCMKTS: OASMY for Cantrixil under development the treatment of ovarian cancer. The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer. 